CMTA’s latest analysis reveals 135 genes and 169 subtypes driving CMT. It offers new insights into the complexity, classification, and future of genetic discovery. Read the story behind the headlines.
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
CMTA-STAR Alliance Partner Applied Therapeutics presented 24-month Phase III data on govorestat for CMT-SORD at PNS 2025, showing sustained clinical benefit, MRI-based disease slowing, and continued safety. These findings support the potential for the first approved treatment for CMT-SORD and mark progress toward an expected NDA submission.
CMT is Not Muscular Dystrophy: Key Differences That Set Them Apart
Charcot-Marie-Tooth disease (CMT) and muscular dystrophy (MD) may seem similar at first glance, both are...
CMT is Not an Autoimmune Disease: Exploring the Key Differences
At first glance, Charcot-Marie-Tooth disease (CMT) and autoimmune diseases may seem similar. Both can cause...
CMT-SORD: Bringing the Science Down to Earth | Shooting Star Ep. 3
Shooting Star makes CMT science easy to understand! In this episode, the CMTA youth group explores CMT-SORD, a rare form of CMT linked to mutations in the SORD gene. Learn how it’s diagnosed, what makes it unique, and why research is gaining momentum. Watch now and stay informed!
CMTA Announces New Center of Excellence at Virginia Commonwealth University
The Charcot-Marie-Tooth Association (CMTA) has designated Virginia Commonwealth University (VCU) as its newest CMTA Center of Excellence. Led by Dr. Nicholas Johnson, the center provides expert multidisciplinary care and advances research to improve the lives of individuals with CMT.
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
CMTA-STAR Alliance Partner NMD Pharma A/S has launched the SYNAPSE-CMT Phase II trial, with the first patient dosed at a CMTA Center of Excellence. This study is evaluating NMD Pharma's NMD670, an investigational therapy aimed at improving nerve-to-muscle communication in adults with CMT1 and CMT2. The trial is now enrolling at sites in the U.S. and Europe. Learn more about how CMTA supports this critical research and how you can get involved.
Statement from CMTA’s Chief Executive Officer, Sue Bruhn, PhD
At CMTA, Community Is Everything. Read CEO Sue Bruhn’s statement on disability rights, research, and how you can support the CMT community today.
